These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 27335404)

  • 1. Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making.
    Groman SM; Smith NJ; Petrullli JR; Massi B; Chen L; Ropchan J; Huang Y; Lee D; Morris ED; Taylor JR
    J Neurosci; 2016 Jun; 36(25):6732-41. PubMed ID: 27335404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.
    Searle G; Beaver JD; Comley RA; Bani M; Tziortzi A; Slifstein M; Mugnaini M; Griffante C; Wilson AA; Merlo-Pich E; Houle S; Gunn R; Rabiner EA; Laruelle M
    Biol Psychiatry; 2010 Aug; 68(4):392-9. PubMed ID: 20599188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2/D3 receptor agonist quinpirole impairs spatial reversal learning in rats: investigation of D3 receptor involvement in persistent behavior.
    Boulougouris V; Castañé A; Robbins TW
    Psychopharmacology (Berl); 2009 Mar; 202(4):611-20. PubMed ID: 18836703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional and source-based patterns of [
    Worhunsky PD; Matuskey D; Gallezot JD; Gaiser EC; Nabulsi N; Angarita GA; Calhoun VD; Malison RT; Potenza MN; Carson RE
    Neuroimage; 2017 Mar; 148():343-351. PubMed ID: 28110088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models.
    Adams RA; Moutoussis M; Nour MM; Dahoun T; Lewis D; Illingworth B; Veronese M; Mathys C; de Boer L; Guitart-Masip M; Friston KJ; Howes OD; Roiser JP
    Cereb Cortex; 2020 May; 30(6):3573-3589. PubMed ID: 32083297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
    Graff-Guerrero A; Redden L; Abi-Saab W; Katz DA; Houle S; Barsoum P; Bhathena A; Palaparthy R; Saltarelli MD; Kapur S
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):273-87. PubMed ID: 19751545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D2/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [(18)F]F-PHNO.
    Vasdev N; Seeman P; Garcia A; Stableford WT; Nobrega JN; Houle S; Wilson AA
    Nucl Med Biol; 2007 Feb; 34(2):195-203. PubMed ID: 17307127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.
    Rabiner EA; Slifstein M; Nobrega J; Plisson C; Huiban M; Raymond R; Diwan M; Wilson AA; McCormick P; Gentile G; Gunn RN; Laruelle MA
    Synapse; 2009 Sep; 63(9):782-93. PubMed ID: 19489048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separating dopamine D
    Smart K; Gallezot JD; Nabulsi N; Labaree D; Zheng MQ; Huang Y; Carson RE; Hillmer AT; Worhunsky PD
    Neuroimage; 2020 Jul; 214():116762. PubMed ID: 32201327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-specific modulation of risk-based decision making by nucleus accumbens dopamine.
    Stopper CM; Khayambashi S; Floresco SB
    Neuropsychopharmacology; 2013 Apr; 38(5):715-28. PubMed ID: 23303055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic modulation of risk-based decision making.
    St Onge JR; Floresco SB
    Neuropsychopharmacology; 2009 Feb; 34(3):681-97. PubMed ID: 18668030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the role of the D3 receptor in addiction? A mini review of PET studies with [(11)C]-(+)-PHNO.
    Payer D; Balasubramaniam G; Boileau I
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():4-8. PubMed ID: 23999545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [(11)C]-(+)-PHNO.
    Boileau I; Nakajima S; Payer D
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1410-20. PubMed ID: 26141509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.
    Le Foll B; Payer D; Di Ciano P; Guranda M; Nakajima S; Tong J; Mansouri E; Wilson AA; Houle S; Meyer JH; Graff-Guerrero A; Boileau I
    Neuropsychopharmacology; 2016 Jan; 41(2):529-37. PubMed ID: 26089182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.
    Matuskey D; Worhunksy P; Correa E; Pittman B; Gallezot JD; Nabulsi N; Ropchan J; Sreeram V; Gudepu R; Gaiser E; Cosgrove K; Ding YS; Potenza MN; Huang Y; Malison RT; Carson RE
    Neuroimage; 2016 Apr; 130():241-247. PubMed ID: 26876475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Dopamine D
    Gaiser EC; Gallezot JD; Worhunsky PD; Jastreboff AM; Pittman B; Kantrovitz L; Angarita GA; Cosgrove KP; Potenza MN; Malison RT; Carson RE; Matuskey D
    Neuropsychopharmacology; 2016 Dec; 41(13):3042-3050. PubMed ID: 27374277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.
    Boileau I; Payer D; Houle S; Behzadi A; Rusjan PM; Tong J; Wilkins D; Selby P; George TP; Zack M; Furukawa Y; McCluskey T; Wilson AA; Kish SJ
    J Neurosci; 2012 Jan; 32(4):1353-9. PubMed ID: 22279219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.